Medications urgently recalled after rodent feces contamination
Gold Star Distribution has urged consumers to report any adverse reactions through the FDA's MedWatch program
A batch of popular cold and flu medications is being recalled from over-the-counter shelves. The recall affects a wide range of health products, dietary supplements, food, and cosmetics, following the discovery of rodent and bird droppings at the Gold Star Distribution, Inc. facility in Minneapolis. Unsanitary conditions have been identified that can lead to bacterial contamination, especially Salmonella, posing a significant risk to infants, the elderly, and people with compromised immune systems. The recall began on December 26, and no illnesses related to the products have been reported to date. The Food and Drug Administration (FDA) advises that those who handle these products could face serious health complications. Consumer Suggestions: The recall, which includes products such as DayQuil, NyQuil, and Tylenol, is limited to items stored at the Gold Star facility. Consumers and retailers should destroy the affected products and submit a receipt for refunds. Gold Star Distribution has urged consumers to report any adverse reactions through the FDA's MedWatch program, and the FDA offers assistance through its hotline to address concerns about the recall.
Products Involved
FDA Follow-Up
The FDA conducts active and formal follow-up after a product recall (such as for drugs, food, medical devices, etc.) to ensure that the company complies with the recall and that the risk to public health is adequately reduced.
First, the FDA classifies the recall based on the health risk:
This classification determines the urgency and extent of the follow-up that the FDA will apply.
Furthermore, The FDA works with the manufacturer or distributor to define a recall strategy, which includes:
The agency reviews and approves the recall plan before it is implemented.
Once the recall has begun, the FDA evaluates its effectiveness. by:
The FDA may also monitor whether the product remains available on the market or if there are any new complaints or adverse events related to it.